FDA approves Mounjaro to lower heart attack and stroke risk in type 2 diabetes

The FDA on August 28, 2026 approved Mounjaro (tirzepatide) for a second job beyond blood sugar control: lowering the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with type 2 diabetes who are at high risk for those events ^[1][4][5]. Eli Lilly's drug was already cleared, alongside diet and exercise, to improve glucose in adults and children 10 and older with the condition ^[1][2].

The trial behind the decision

SURPASS-CVOT enrolled 13,299 adults who had type 2 diabetes plus established atherosclerotic cardiovascular disease, recruiting at 640 sites across 30 countries ^[1][4]. Half received tirzepatide at 15 mg or the highest dose they could tolerate; half received dulaglutide (Trulicity) 1.5 mg. Both were weekly injections, and participants stayed in the study for a median of 210.1 weeks, a bit past four years ^[1][4].

The design set this trial apart. Instead of pitting tirzepatide against a placebo, researchers measured it against dulaglutide, a GLP-1 medicine whose cardiovascular benefit was already established. Lilly calls it the first time two incretin therapies went head-to-head in an outcomes trial ^[1][4][5].

Results showed an 8% lower rate of the three-part composite — cardiovascular death, heart attack or stroke — with tirzepatide. The hazard ratio for a first event was 0.92, with a 95.3% confidence interval of 0.83 to 1.01 ^[1][4]. AJMC reported the interval as 0.83-1.01 and estimated the composite occurred in about 12% of tirzepatide users versus 13% of those on dulaglutide ^[5]. Tirzepatide cleared the pre-specified non-inferiority bar; the data did not establish superiority over dulaglutide ^[1][4][5]. Full findings appeared in The New England Journal of Medicine ^[1][4].

"We set a higher bar by testing Mounjaro against a GLP-1 medicine with proven cardiovascular benefit," said Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health ^[1][4].

Lilly said the drug's tolerability matched its existing profile, with gastrointestinal reactions most common, generally mild to moderate, and clustered during the period when doses ramp up ^[1][4]. The prescribing information keeps a boxed warning about thyroid C-cell tumors and lists nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain among common reactions ^[2]. The label revision is dated August 27, 2026, and also includes an updated caution about diabetic retinopathy in patients with a history of the condition ^[2].

Why it matters for patients

Heart disease is the leading cause of death for people with type 2 diabetes, and Lilly estimates that as many as one in three US adults with the condition have cardiovascular disease that has not been detected ^[1][4]. For the high-risk group, the prescribing information now names reducing heart attack, stroke and cardiovascular death as an approved use rather than an observed trend ^[1][2]. Lilly and AJMC describe Mounjaro as the first dual GIP and GLP-1 receptor agonist with this kind of FDA-cleared claim ^[1][4][5].

What the approval does not say matters too. The claim rests on matching an active comparator, not beating it, and the confidence interval around the hazard ratio crossed 1.0, the usual threshold for statistical significance ^[1][4][5]. Patients comparing options may want to know the comparison arm received dulaglutide, which itself carries a cardiovascular risk-reduction indication, rather than a placebo ^[1][4].

The new indication covers adults only. Children 10 and older can still take Mounjaro for blood sugar, but not under a cardiovascular claim ^[1][2].

What happens next

Mounjaro's product information in the European Union already includes the SURPASS-CVOT data, and Lilly has submissions based on the trial under review in additional markets ^[1][4]. The company has not disclosed further FDA action dates or post-approval study requirements tied to this US decision ^[1][4].